Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-719 for Prevention of AKI in High-Risk Cardiac Surgery
NCT01777165Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2013
- Primary completion
- Mar 2014
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of modimelanotide in acute kidney injury (AKI) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Incidence of Acute Kidney Injury based on AKIN criteria at 7 days. Started Feb 2013; status: completed.
02
Drugs
modimelanotide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT01777165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777165.